CLChun-Xiao Liu

Chun-Xiao Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chun-Xiao Liu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 November 2015
      • Vol. 35  (11) , 1524-9

    [Effect of stable DNA methyltransferase 3bknockdown on proliferation and apoptosis in bladder cancer cells in vitro].

    by Ke Chen, Bing-Kun Li, Kai Xu, Abai Xu, Chunxiao Liu, Shaobo Zheng, Yawen Xu, Chenyao Jia, Qi Liu, Hulin Li

    To investigate the effect of stable knockdown of DNA methyltransferase 3b (DNMT3b) on the proliferation and apoptosis of bladder cancer cells. Lentivirus expressing DNMT3b siRNA or the negative control siRNA was infected in human bladder cancer BIU-87 cells. MTT assay and flow cytometry were used to detect cell proliferation and apoptosis, respectively. The inhibitory effect of DNMT3b knockdown on xenograft tumors in nude mice was observed. Real-time PCR and Western blotting were carried out to investigate the expression level of cell apoptosis related genes. Methylation specific PCR was used to examine the methylation in the promoter region of the cell apoptosis related genes. The results of real-time PCR and Western blotting showed that DNMT3b mRNA and protein level were stably knocked down in BIU-87 cells. Stable DNMT3b knockdown suppressed BIU-87 cell growth and the tumor formation ability of the cells in nude mice. DNMT3b knockdown promoted the apoptosis of BIU-87 cells, increased the mRNA and protein expression of the cell growth and apoptosis related genes including DAPK, Bax and RASSF1A, and significantly decreased the methylation of these genes. Stable DNMT3b knockdown can affect the methylation of the cell growth and apoptosis related genes to regulate their expression, which might be a possible mechanism for suppressed cell growth and enhanced apoptosis of BIU-87 cells.


    • 1 April 2013
      • Vol. 33  (4) , 550-3

    [Expression of myeloid-derived suppressor cells in the peripheral blood and its clinical significance in renal carcinoma].

    by Songqing Feng, Chunxiao Liu, Shaobo Zheng, Peng Huang, Binshen Chen, Kai Guo

    To investigate the expression of CD33⁺ HLA-DR⁻ myeloid-derived suppressor cells (MDSCs) in the peripheral blood of patients with renal carcinoma and its correlation with the clinicopathological features of renal cancer. Forty-four patients with renal carcinoma treated in our hospital between June, 2011 and October, 2012 and 18 healthy volunteers were enrolled in this study. Flow cytometry was performed to detect CD33⁺ HLA-DR⁻ MDSCs in the peripheral blood, and its correlation with the clinicopathological features of the patients were analyzed. The positivity rate of CD33⁺ HLA-DR⁻ MDSCs in the peripheral blood was significantly higher in the cancer patients than in the healthy controls [(1.91 ± 0.66)% vs (0.62 ± 0.22)%, P<0.001]. The expression levels of CD33⁺ HLA-DR⁻ MDSCs in patients with renal carcinoma showed significant differences between stage I+II [(1.46 ± 0.44)%] and stage III [(2.04 ± 0.35)%] patients (P<0.01) and between stage III and stage IV patients [(2.50 ± 0.64)%] (P<0.05), but did not differ significantly in respect of age or gender. CD33⁺ HLA-DR⁻ MDSCs expression in the peripheral blood is associated with tumor stage and differentiation in renal carcinoma and may play an important role in predicting the prognosis and tumor immunology of renal carcinoma.


  • Suppression of IGHG1 gene expression by siRNA leads to growth inhibition and apoptosis induction in human prostate cancer cell

    by Bin Pan, Shaobo Zheng, Chunxiao Liu, Yawen Xu

    To investigate the immunoglobulin G (IgG) expression in prostate cancer cell lines and explore the effects of IGHG1 gene knockdown on PC3 cell growth and apoptosis. Flow cytometry, qPCR and western blot were used to demonstrate IgG expression in prostate cancer cell lines. PC3 cells were transfected with designed siRNA, the expression of IgG was determined by qPCR and western blot, the proliferation and apoptosis were detected by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenil)-2H-tetrazolium, inner salt (MTS) and flow cytometry. The percentages of IgG in LNCaP cell membrane and cytoplasm were 2.96 and 89.22 % by flow cytometer, those of PC3 cell were 86.73 and 90.99 % respectively. The average level of IgG1 mRNA expression in PC3 cell line was significantly higher than that in LNCaP cell line (3.08 ± 0.15 vs 1.00 ± 0.37, P = 0.001). The protein level of IgG expression of PC3 cell line was 1.92 ± 0.15, compared with LNCaP cell line (1.05 ± 0.86). The expression of IgG1 mRNA and protein level in transfected PC3 cells decreased, with significant statistical differences from the blank control group (P < 0.01). The PC3 cell growth inhibition rates were 31.3 and 43.3 % in 48 and 72 h respectively. The rate of apoptotic PC3 cells were 5.29 ± 0.41 % in experimental group higher than that in control group (1.49 ± 0.29 %) (P < 0.01). IgG was identified in prostate cancer cells, and the siRNA targeted silencing of IGHG1 can inhibit cell viability and promote apoptosis, which might therefore act as a potential target in prostate cancer gene therapy.


    • 1 October 2012
      • Vol. 32  (10) , 1461-4

    [Effect of docetaxel on C-jun and androgen receptor interaction in prostate cancer LNCaP cells and its androgen-independence subtype LNCaP-bic cells].

    by Binshen Chen, Yawen Xu, Abai Xu, Chunxiao Liu, Shaobo Zheng, Hulin Li, Kai Xu

    To investigate the effect of docetaxel on the interaction between C-jun and androgen receptor (AR) in prostate cancer LNCaP cells and its androgen-independence subtype LNCaP-bic cells. LNCaP and LNCaP-bic cells were treated with docetaxel and the changes in AR and AP-1 expression were evaluated using luciferase assay. Western blotting and immunoprecipitation assay were employed to analyze the effects of docetaxel on the expressions of C-jun and AR and their interaction. Luciferase assay showed that LNCaP and LNCaP-bic cells expressed higher levels of AR and C-jun after docetaxel treatment. Docetaxel induced a higher level of p-c-jun expression in LNCaP-bic cells than in the parental LNCaP cells. Western blotting showed a strong PSA protein expression in LNCaP-bic cell after docetaxel treatment. Docetaxel caused a stronger interaction between AR and C-jun in LNCaP-bic cells. Docetaxel activates ligand-independent AR transcription, and the interaction between AR and C-jun may affect the outcome of docetaxel chemotherapy.


    • 1 May 2012
      • Vol. 32  (5) , 643-6

    [Expression of OCT4 protein in bladder cancer and its clinicopathological implications].

    by Pengpeng Zhao, Chunxiao Liu, Kai Xu, Shaobo Zheng, Hulin Li, Yawen Xu, Abai Xu, Bingkun Li, Peng Huang

    To study the expression of OCT4 protein in bladder cancer and its correlation to the clinicopathologic features and prognosis of bladder cancer. OCT4 mRNA and protein expression was detected in 5 bladder cancer cell lines (RT-4, Tcc-Sup, KK47, T24, and 5637) and 1 normal bladder cell lines by real-time PCR and Western blotting, respectively. Immunohistochemical analysis was used to detect the expression of OCT4 protein in 46 bladder cancer samples. All the 5 bladder cancer cell lines expressed detectable levels of OCT4 mRNA and proteins, whereas the normal bladder cell line SV-HUC-1 was negative for OCT4 expression. The clinical bladder cancer tissues showed a high positivity rate of OCT4 expression (76.1%), which was not detected in normal bladder tissues. Specific OCT-4 signals were localized mainly in the nuclei of the cancer cells. The expression rate of OCT4 protein was significantly higher in bladder cancer tissue than in normal bladder epithelium (P<0.05), and showed a positive correlation to the grade of tumor differentiation and metastasis (P<0.05) but not to the patients' age, gender or TNM stage. OCT4 protein expression is associated with tumor differentiation and metastasis in bladder cancer and may play an important role in the early diagnosis and prognostic evaluation of bladder cancer.


    • 1 February 2012
      • Vol. 32  (2) , 226-9

    [Laparoendoscopic single-site retroperitoneal lymph node dissection: initial experience and 1-year follow-up].

    by Abai Xu, Hulin Li, Shaobo Zheng, Guoping Zhao, Haiyan Shen, Chunxiao Liu

    To summarize our initial experience with laparoendoscopic single-site (LESS) retroperitoneal lymph node dissection (RPLND) for treatment of nonseminomatous testicular cancer. From September 2010 to June 2011, 3 patients (aged 19-27 years) with right testicle enlargement and elevated alpha-fetoprotein level underwent right radical orchidectomy. Histopathological analysis revealed nonseminomatous germ cell tumor. LESS-RPLND was performed 3 weeks after orchiectomy. The homemade port was inserted through a 3-cm right pararectal incision in the right lower quadrant for unilateral RPLND using nerve-sparing technique and modified right-sided template removal similar to those in open RPLND. The operation was successfully performed with a mean operative time of 240 min and a mean estimated blood loss of 50 ml. No conversion to open or conventional laparoscopic surgery was required. No major perioperative complications were observed. For the first case, the number of lymph nodes obtained for final histopathological examination was 11, and two positive nodes were detected. For the other 2 cases, no positive nodes were detected. Chemotherapy was administered in the first case. Alpha-fetoprotein level decreased close to the baseline one week postoperatively and no relapse occurred in these cases 3 month after RPLND. Follow-up at 1 year after the surgery showed good tumor control and preservation of the sexual function. LESS-RPLND is safe and feasible for treatment of nonseminomatous testicular cancer, and the pararectal incision provides an ideal surgical approach with good cosmetic result, but the long-term effect needs to be tested by further large population-based study.

    • 1 February 2012
      • Vol. 32  (2) , 274-6

    [Single-port laparoscopic surgery for radical nephrectomy: report of 22 cases].

    by Hulin Li, Abai Xu, Kai Xu, Binshen Chen, Chunxiao Liu, Shaobo Zheng, Yawen Xu, Ping Fang, Kai Guo, Yangyan Lin, et al.

    [corrected] To evaluate the method and technique of single-port laparoscopic radical nephrectomy. Form January 2009 to September 2011, 22 patients with renal carcinoma were treated with single-port laparoscopic radical nephrectomy. An incision about 5 cm in length was made through the umbilicus or in the postaxillary line under the 12th rib to establish the peritoneal or retroperitoneal working space. A single-port cannulation was deployed and the operation was carried out using standard and crooked laparoscopic equipment. The operations were completed successfully in all the 22 cases without conversion to open surgery, but additional trocar was needed in 5 cases. The mean operative time of radical nephrectomy was 150 min (90-240 min). The mean postoperative hospital stay was 7.6 days (3-15 days). The operation left a roughly 5-cm-long scar in all the cases. Single-port laparoscopic radical nephrectomy is safe and feasible with good cosmetic effect and shows much potential in radical resection of renal carcinoma.

    • 1 June 2011
      • Vol. 31  (6) , 933-6

    [Laparoendoscopic single-site surgery for male pseudohermaphroditism: the initial report].

    by Yong Wen, A-Bai Xu, Shao-Bo Zheng, Chun-Xiao Liu, Ya-Wen Xu, Hu-Lin Li, Kai Xu, Ping Fang, Chuan-Yin Li

    To evaluate the therapeutic effect of laparoendoscopic single-site surgery (LESS) for treatment of male pseudohermaphroditism. A 17-year-old patient with male pseudohermaphroditism and a female social sex was admitted. According to the request by the patient and the relatives for a female gender, LESS vaginoplasty and cryptorchidectomy were performed using a single multilumen port inserted through a 2.5 cm incision below the umbilicus, followed by reconstruction of the perineal region by open surgery. The total operative time was 7 h, and the LESS procedure lasted for about 3.5 h. No other port incision was needed. The estimated intraoperative blood loss was 400 ml. No electrolyte or metabolic acid-base balance disorders were observed perioperatively. In the follow-up examination at 6 months after the operation, the reconstructed vagina healed smoothly without obvious contraction or fixation failure, and the perineal region showed good appearance. With minimal invasiveness, LESS surgery produces good cosmetic effect and allows rapid postoperative recovery, thus may become a promising alternative to the management of pseudohermaphroditism.

    • 1 December 2010
      • Vol. 30  (12) , 2708-10

    [Transurethral enucleation of the prostate for treatment of benign prostatic hyperplasia in patients less than 50 years old].

    by Ya-Wen Xu, Chun-Xiao Liu, Shao-Bo Zheng, Hu-Ling Li, Ping Fang, Bin-Shen Chen, Kai Xu, Hai-Yan Shen

    To evaluate the therapeutic effect of transurethral enucleation of the prostate for treatment of benign prostatic hyperplasia in patients below 50 years of age. Twelve patients with benign prostatic hyperplasia patients (mean age 48.2 years, range 46-49 years) underwent transurethral enucleation of the prostate. The middle lobe and two lateral lobes were enucleated with the preprosthetic sphincter and anterior fibromuscular stroma preserved during the operation. The patients were followed up to evaluate the lower urinary tract symptoms and sexual activity after the surgery. The 12 patients were followed up for 3 to 6 months. The symptoms of lower urinary tract obstruction were improved obviously after the surgery, and the International Prostate Symptom Score (IPSS) decreased from 24±5.1 to 8.8±1.4 and peak urine flow rate (Qmax) increased from 8.1±4.2 ml/s to 20.1±4.2 ml/s at 3 months postoperatively. All the 12 cases had residual urine (12-44 ml) preoperatively, but after the surgery, only 4 still had residual urine of less than 30 ml. All the patients had normal erection function postoperatively, and 10 had normal ejaculation; the other 2 patients recovered normal ejaculation 3 and 5 months after the operation, respectively. Transurethral enucleation can alleviate the low urinary tract obstruction symptom and improve the sexual function by avoiding preprosthetic sphincter injury in relatively young patients with benign prostatic hyperplasia.


    • 1 June 2010
      • Vol. 30  (6) , 1389-91, 1394

    [Expression of special AT-rich sequence-binding protein in bladder urothelial carcinoma and its clinical significance].

    by Chun-Xiao Liu, Yong Wen, Kai Xu, Shao-Bo Zheng, Ya-Wen Xu, Bin-Shen Chen

    To detect the expression of special AT-rich sequence-binding protein (SATB1) in bladder urothelial carcinoma and investigate its correlation to the biological behavior of the carcinoma. The expression of SATB1 mRNA was detected in 34 cases of bladder urothelial carcinoma and 14 normal bladder tissues by RT-PCR, and the protein expression of SATB1 was detected in 68 cases of bladder urothelial carcinoma and 17 normal bladder tissues by immunohistochemistry. The correlation between SATB1 expressions and the biological behavior of the tumor was analyzed. The expression of SATB1 was significantly higher in bladder urothelial carcinoma tissues than in normal bladder tissues (P<0.05). and the expression of SATB1 in the tumor tissues was correlated to the clinical stage and metastasis of the tumor. SATB1 expression can be associated with the development and metastasis of bladder urothelial carcinoma and may potentially serve as an indicator for predicting the prognosis of bladder urothelial carcinoma.